E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the feasibility of submandibular duct ligation right after intraductal ethanol infusion into the submandibular salivary gland |
|
E.2.2 | Secondary objectives of the trial |
The secondary aims of the study are to evaluate effect, and to evaluate whether an out-patient setting is suitable for the procedure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Moderate to severe drooling indicated by Drooling Frequency Score ≥ 3 or Drooling Severity Score ≥ 2. 2. Aged 10 years and older. 3. Cerebral palsy or any other non-progressive neurodevelopmental disability. 4. Contra-indications for a SMDR, or rejection towards a SMDR by patient or caregiv-ers* 5. Ability and willingness to follow the study protocol and attend the 8 and 32-weeks vis-its. 6. Written and informed consent from caregivers, and when appropriate, oral consent from the child. * contra-indication for SMDR: - posterior drooling - pharyngeal dysphagia as judged by the speech and language therapist. - progressive neurodisability as judged by the child neurologist.
|
|
E.4 | Principal exclusion criteria |
1. Medical history of salivary gland abnormalities like ductal stenosis, strictures 2. Previous submandibular salivary gland surgery, or other contraindications for surgery or general anesthesia. 3. Recent (<6 months) glandular Botulinum Neurotoxin A (BoNT-A) injection 4. Simultaneous alternative treatment for drooling. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
a. Adverse events. b. Post-operative complaints c. Surgical time.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
baseline, 8 and 32 weeks. |
|
E.5.2 | Secondary end point(s) |
All parameters will be compared to the previous results of 2-DL without infusion of ethanol in this institution.
Secondary study parameters. The following five variables will be collected as standard care although these are not among the outcomes of the current study.
1. Visual Analog Scale for the severity of drooling 2. Drooling Quotient 3. Treatment effect 4. Drooling Severity Scale 5. Drooling Frequency Scale 6. Costs
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Pilot study. No comparison. |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
In accordance to section 10, subsection 4, of the WMO, the investigator will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. The investigator will notify the accredited METC without undue delay of a temporary halt including the reason for such an action. The study will be suspended pending a further positive decision by the accredited METC. The investigator will take care that all subjects are kept informed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |